RADICAL INNOVATION OVER RADICAL INTERVENTION: TRANSFORMING LOCAL THERAPIES IN URO-ONCOLOGY

Our Company is focused on research and development of therapies in uro-oncology for the following conditions

LG UTUC

Low-Grade Upper Tract Urothelial Carcinoma

LG UTUC is a rare urothelial tumor affecting approximately 3,000 new patients each year. Read More

LG NMIBC

Low-Grade Non-Muscle Invasive Bladder Cancer

Bladder cancer accounts for approximately 90% to 95% of all new cases of urothelial cancer in the United States.  Read More

CIS

Carcinoma in Situ of the Bladder, a form of High-Grade NMIBC

HG NMIBC is a highly aggressive form of bladder cancer. Read More

News and Announcements

UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

Clinical Trials

UTUC

The OLYMPUS study

Optimized DeLivery of Mitomycin for Primary UTUC Study

Enrollment Complete

Read further information on the clinical study

BLADDER CANCER

The OPTIMA study II

OPTimized Instillation of Mitomycin for BlAdder Cancer Treatment

Currently Enrolling Patients

Read further information on the clinical study

About UroGen Pharma

UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™ reverse thermal hydrogel, a novel technology that is liquid when chilled, but gels at body temperature. We believe RTGel technology has the potential to be applied to a variety of unmet medical needs where increased exposure to the active drug would improve the therapeutic profile of existing drugs, making local therapy a potentially more effective treatment option. UroGen’s lead investigational candidates, UGN-101 (mitomycin gel) for instillation, and UGN-102 (mitomycin gel) for intravesical instillation, are designed to potentially chemoablate tumors, a method that utilizes intervention without surgical removal or resection, and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and bladder cancer, respectively. UroGen is headquartered in New York, NY with operations in Los Angeles, CA and Israel.

Contact

UroGen Pharma
499 Park Avenue, Suite 1200
NY 10022, U.S.A
+1-646-768-9780 ext 1001